• SU6656 Src Tyrosine Kinases Inhibitor: Redefining Platelet a

  2026-06-23

  Explore the scientific depth and distinct capabilities of SU6656, a selective Src tyrosine kinases inhibitor, in enhancing platelet biomanufacturing and radiotherapy. This article delivers advanced mechanistic insight, practical protocol guidance, and a critical evaluation of current breakthroughs in cancer and regenerative research.

• Reliable Cell Assays with Mifepristone (RU486): Scenario Sol

  2026-06-22

  This article provides evidence-based guidance for life science researchers using Mifepristone (RU486) (SKU B1511) in cell viability, proliferation, and cytotoxicity assays. Scenario-driven Q&A blocks address common laboratory challenges—ranging from protocol optimization to vendor selection—demonstrating how Mifepristone from APExBIO delivers reproducible results and practical workflow advantages.

• Bcl-xL Maintains Chemoresistant Quiescence in Pancreatic Can

  2026-06-22

  This study reveals that Bcl-xL enforces a slow-cycling, metabolically adapted state in pancreatic cancer cells, enabling their survival under nutrient deprivation and conferring resistance to chemotherapy. The findings provide a rationale for therapies that target both proliferative and quiescent tumor populations, potentially improving treatment outcomes.

• Genistein, Cytoskeletal Autophagy, and Translational Oncolog

  2026-06-21

  This article explores how Genistein, a selective protein tyrosine kinase inhibitor, intersects with recent mechanistic advances in cytoskeleton-dependent autophagy. By drawing on newly published research and strategic guidance, the piece highlights Genistein’s role in translational cancer studies, providing actionable recommendations for protocol design and competitive positioning. References to APExBIO’s product intelligence and related literature contextualize Genistein’s unique value for oncology workflows.

• Nuclear Condensate Formation by Drosophila Keap1 Under Oxida

  2026-06-20

  This study reveals that Drosophila Keap1 (dKeap1) assembles into nuclear condensates in response to oxidative stress, providing new insight into the nuclear functions of Keap1 beyond its classic cytoplasmic role. The work highlights domain-specific mechanisms underlying condensate formation, with implications for chromatin regulation and stress adaptation.

• CB-839 (Telaglenastat) in Cancer Metabolism: Mechanism & Evi

  2026-06-19

  CB-839 (Telaglenastat) is a selective, orally bioavailable glutaminase 1 inhibitor that disrupts glutaminolysis, impairing cancer cell survival. Recent evidence links GLS1 inhibition by CB-839 to metabolic vulnerabilities in aggressive cancers, offering robust preclinical efficacy. This article summarizes mechanisms, benchmarks, and workflow recommendations for CB-839 (Telaglenastat) in cancer metabolism research.

• Foretinib (GSK1363089): Optimizing Tumor Cell Growth Inhibit

  2026-06-19

  Foretinib (GSK1363089) stands out as a potent ATP-competitive multikinase inhibitor for dissecting tumor cell proliferation and metastasis in advanced cancer models. This article demystifies practical workflows, protocol refinements, and troubleshooting strategies for researchers leveraging Foretinib in in vitro and in vivo oncology studies.

• Applied Angiotensin 1/2 (2-7) Peptide Workflows in RAS Resea

  2026-06-18

  Harness the high-purity Angiotensin 1/2 (2-7) peptide to drive reproducible breakthroughs in blood pressure and viral interaction models. This guide blends protocol precision with troubleshooting strategies, equipping researchers to unlock new layers of renin-angiotensin system biology.

• L-Ornithine in CNS Metabolic Research: Protocols & Enhanceme

  2026-06-18

  L-Ornithine ((S)-2,5-diaminopentanoic acid) enables advanced modeling of urea cycle disruptions and ammonia detoxification in CNS and hepatic research. This guide distills the latest mechanistic findings and practical workflows, offering troubleshooting and optimization strategies for reliable, reproducible results.

• Rapid Pharmacological Conversion of AF: Vernakalant Phase 3

  2026-06-17

  This article examines the pivotal phase 3 trial evaluating vernakalant hydrochloride for acute conversion of atrial fibrillation (AF), emphasizing its atrial selectivity, rapid action, and safety profile. The findings offer important context for researchers studying adrenergic signaling, antiarrhythmic strategies, and translational cardiovascular therapies.

• RP3-340N1.2 Knockdown Destabilizes IL-6 in NSCLC Progression

  2026-06-17

  This study identifies the long non-coding RNA RP3-340N1.2 as a critical driver of non-small cell lung cancer (NSCLC) progression through stabilization of IL-6 mRNA. Knockdown of RP3-340N1.2 enhances IL-6 mRNA degradation via increased ZC3H12A binding, suppressing tumor cell proliferation, migration, and macrophage polarization—offering a potential therapeutic target in NSCLC.

• Phenothiazines Enhance Macrophage Antibacterial Activity via

  2026-06-16

  This study demonstrates that phenothiazines significantly boost macrophage antibacterial function by inducing reactive oxygen species (ROS) and autophagy. The findings offer a mechanistic rationale for repurposing phenothiazines as host-directed therapies (HDTs) against intracellular bacterial infections, with implications for antibiotic resistance management.

• Captopril (SKU A4078): Best Practices for Reliable ACE Inhib

  2026-06-16

  This article provides scenario-driven, evidence-based guidance for biomedical researchers using Captopril (SKU A4078) in cell viability, proliferation, and cytotoxicity assays. Drawing on high-purity product data and primary literature, it addresses experimental design, optimization, data interpretation, and vendor selection—empowering labs to achieve reproducible results with validated ACE inhibition strategies.

• Rocilinostat (ACY-1215): Precision HDAC6 Inhibitor for Myelo

  2026-06-15

  This article provides evidence-based guidance for optimizing cell viability and cytotoxicity assays using Rocilinostat (ACY-1215), SKU A4083. Through scenario-driven Q&A, we address common technical hurdles and recommend practical solutions to maximize reproducibility and data fidelity in HDAC6-related cancer research.

• AIBP-LRP2 Axis Regulates Collateral Circulation via HDL Upta

  2026-06-15

  Zhu et al. define a novel two-phase mechanism by which AIBP-LRP2–mediated HDL uptake restricts the expansion of CXCR4+ stemlike capillary endothelial cells, thereby controlling collateral vessel formation in ischemic disease. Their work reveals a lipid metabolism–driven regulatory pathway with implications for therapeutic revascularization.

456 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page